WEST HAVEN, Conn.--(BUSINESS WIRE)--July 31, 2006--Anil Diwan, PhD, NanoViricides' (Pink Sheets: NNVC - News) President, today commented that, "The GSK vaccine has shown significantly better efficacy than the previous vaccines. The GSK vaccine showed an 80% protection in treated individuals. This is still far less than the 95% or better usual clinical protection level of annual influenza vaccines. Using the 80% protection rate, approximately 50% of the population may be expected to show H5N1 bird flu pathology even if a vaccine campaign with the GSK vaccine covered 100% of the world population. The high rates of emergence of resistant viral mutants with existing and developing neuraminidase inhibitor therapies such as Tamiflu(TM), Relenza(TM), or Peramivir(TM), make these therapies unsuitable for widespread strategic use in pandemic containment. In contrast, pre-clinical studies lead us to believe that most of such patients would be curable with our experimental anti-influenza nanoviricides drugs; AviFluCide(TM)-I and FluCide(TM)-I."
